Patents by Inventor Osamu Tenmyo
Osamu Tenmyo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5466450Abstract: A novel antibiotic complex designated BU-4224V produced by fermentation of Kibdelosporangium albatum sp. nov. Strain R761-7. The complex may be separated chromatographically into bioactive components designated BU-4224V A, B.sub.1, B.sub.2, and C. The components BU-4224V B.sub.1 and B.sub.2 display both antiviral and antimicrobial activity, while component BU-4224V A has antimicrobial activity and component BU-4224V C has antiviral activity.Type: GrantFiled: July 20, 1993Date of Patent: November 14, 1995Assignee: Bristol-Myers Squibb Co.Inventors: Mitsuaki Tsunakawa, Tetsuro Yamasaki, Koji Tomita, Osamu Tenmyo
-
Patent number: 5286649Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.Type: GrantFiled: January 10, 1992Date of Patent: February 15, 1994Assignee: Bristol-Myers Squibb Co.Inventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5266600Abstract: The present invention provides BU-4641V of the formula: ##STR1## This invention also provides a biologically pure culture of BU-4641V producing Arthrinium sp. FA1744. Another aspect of the invention provides a process for preparing BU-4641V. Yet further aspect of the present invention provides a method for treating mammalian tumors and bacterial or viral infections.Type: GrantFiled: October 30, 1992Date of Patent: November 30, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Osamu Tenmyo, Yosuke Sawada, Toshikazu Oki, Masahisa Oka, Masaru Sugawara, Noriyuki Ohkusa
-
Patent number: 5266588Abstract: Disclosed is a novel compound, designated BU-4514N, which is produced by cultivation of a novel strain of Microtetraspora, designated species T689-92. The novel compound possesses antibacterial and neuritogenic properties.Type: GrantFiled: September 25, 1992Date of Patent: November 30, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Soichiro Toda, Takashi Tsuno, Satoshi Yamamoto, Toshifumi Hasegawa, Osamu Tenmyo, Mary P. Rosser
-
Patent number: 5256646Abstract: A novel antibiotic complex designated BU-4224V produced by fermentation of Kibdelosporangium albatum sp. nov. Strain R761-7. The complex may be separated chromatographically into bioactive components designated BU-4224V A, B.sub.1, B.sub.2, and C. The components BU-4224V B.sub.1 and B.sub.2 display both antiviral and antimicrobial activity, while component BU-4224V A has antimicrobial activity and component BU-4224V C has antiviral activity.Type: GrantFiled: July 27, 1990Date of Patent: October 26, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Mitsuaki Tsunakawa, Tetsuro Yamasaki, Koji Tomita, Osamu Tenmyo
-
Patent number: 5256548Abstract: There is provided a new antiviral antibiotic designated herein as BU-4344V which is produced by fermentation of a BU-4344V-producing strain of a new microorganism, Actinomadura parvosata subsp. kistnae ATCC No. 55076. Antibiotic BU-4344V is recovered and purified from the fermentation broth by use of extraction, chromatography, and crystallization techniques. BU-4344V has been found to have some antibacterial activity and inhibits the growth of viruses, including influenza virus type A.Type: GrantFiled: April 27, 1992Date of Patent: October 26, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Masahisa Oka, Koji Tomita, Osamu Tenmyo, Nobuaki Naruse
-
Patent number: 5140101Abstract: There is provided a new antiviral antibiotic designated herein as BU-4344V which is produced by fermentation of a BU-4344V-producing strain of a new microorganism, Actinomadura parvosata subsp. kistnae ATCC No. 55076. Antibiotic BU-4344V is recovered and purified from the fermentation broth by use of extraction, chromatography, and crystallization techniques. BU-4344V has been found to have some antibacterial activity and inhibits the growth of viruses, including influenza virus type A.Type: GrantFiled: November 21, 1990Date of Patent: August 18, 1992Assignee: Bristol-Myers Squibb CompanyInventors: Masahisa Oka, Koji Tomita, Osamu Tenmyo, Nobuaki Naruse
-
Patent number: 5124150Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.Type: GrantFiled: March 11, 1991Date of Patent: June 23, 1992Assignee: Bristol-Myers Squibb Co.Inventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5098708Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.Type: GrantFiled: July 6, 1990Date of Patent: March 24, 1992Assignee: Bristol-Myers Squibb CompanyInventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
-
Patent number: 4803224Abstract: There is disclosed an antibiotic complex designated as BU-2231 V which is produced by fermentation of a BU-2231-producing strain of Streptoalloteichus hindustanus, ATCC 31158. Complex BU-2231 V is recovered and purified from the fermentation broth by use of ion exchange chromatography techniques. Structural analysis shows that the complex is a mixture of components which are .gamma.-homopolymers of D-.alpha.,.gamma.-diaminobutyric acid having an average molecular weight of from about 5,100 to about 5,200. BU-2231 V has been found to be effective to inhibit growth of various Gram-positive and Gram-negative bacteria and of the herpes simplex virus.Type: GrantFiled: May 1, 1986Date of Patent: February 7, 1989Assignee: Bristol-Myers CompanyInventors: Osamu Tenmyo, Hiroaki Ohkuma, Masataka Konishi
-
Patent number: 4314028Abstract: Addition of certain amine precursor compounds to the culture medium during fermentation of a tallysomycin-producing strain of Streptoalloteichus hindustanus results in production of new tallysomycin derivatives having advantageous antimicrobial and antitumor properties.Type: GrantFiled: January 3, 1980Date of Patent: February 2, 1982Assignee: Bristol-Myers CompanyInventors: Takeo Miyaki, Osamu Tenmyo, Masataka Konishi, Hiroshi Kawaguchi
-
Patent number: 4246400Abstract: Addition of certain amine precursor compounds to the culture medium during fermentation of a tallysomycin-producing strain of Streptoalloteichus hindustanus results in production of new tallysomycin derivatives having advantageous antimicrobial and antitumor properties.Type: GrantFiled: July 13, 1979Date of Patent: January 20, 1981Assignee: Bristol-Myers CompanyInventors: Takeo Miyaki, Osamu Tenmyo, Masataka Konishi, Hiroshi Kawaguchi